BOL: Related items

Live Webinar on RNA-Seq Data Analysis on 9 Nov 2016

Strand — Wed, 19 Oct 2016 05:25:27 -0500

Live Webinar on RNA-Seq Data Analysis

Abstract: Strand NGS supports an extensive workflow for the analysis and visualization of RNA-Seq data. The workflow includes Transcriptome / Genome alignment, Differential expression analysis with Statistical approach and Splicing events detection. Strand NGS also supports novel discovery like identification of novel genes, exons and Novel splice junctions, alongside it can also detect gene fusion events. Further downstream analysis such as GO and pathway analysis can be performed on the set of interesting genes. The product has an option to create pipelines for time consuming jobs which automates analysis and leaves more time for end data interpretation. This webinar will give an overview of the features in the RNA-Seq data analysis workflow in Strand NGS and also highlights on parameters within each feature that can be optimized depending on datasets and analysis needs.

Speaker: Mr. Sugandan Sivamani, Senior Application Scientist, Strand Life Sciences

Date: 9th Nov, Session 1 for SAPK/ APFO: 2:30 PM IST Date: 9th Nov, Session 2 for AFO/ EMEA: 9:00 AM PST

Webinar: Unravelling complex mutational events in clinical cases using the power of NGS data analysis by Dr Satish Sankaran on 31 Jan 2018

Strand — Tue, 26 Dec 2017 02:00:26 -0600

Live webinar on Unravelling complex mutational events in clinical cases using the power of Next generation sequencing data analysis by Dr Satish Sankaran on 31 Jan 2018 at 9am CET and 8am PST

Speaker: Dr. Satish Sankaran, Vice President and Lab Director - Clinical Operations & Clinical Lab, Strand Life Sciences Pvt Ltd

Abstract: Next Generation sequencing has come a long way in aiding genetic disease diagnosis by bringing down both the time and cost of testing. Testing involves massively parallel sequencing of a single to 100s of genes in a one assay. With a large amount of sequence data getting generated from such assays, it is critical that the data is analyzed using standard analysis tools to detect wide range of variants. Strand Life Sciences, has tested more than 3000 clinical samples using multi-gene panels for diagnosis of rare disease conditions. NGS data analysis is done using the Strand NGS software and variant prioritization and reporting using StrandOMICS.

While most analysis software can easily detect single nucleotide variants, the complex ones involving insertions and deletions are usually missed. With multiple iterations the Strand NGS software is trained to effectively detect structural and copy number changes from a single NGS data set. This is critical in certain disease conditions like Retinoblastoma and Duchenne’s Muscular Dystrophy where there are clinically relevant deletions reported.

In this presentation, we present four different case studies where we were able to detect mutations due to unusual and difficult regions in the genome from the NGS data. These results were further confirmed using orthologous methods.

Session 1: 31 Jan 2018; 9:00 AM CET
Session 2: 31 Jan 2018; 8:00 AM PST

Webinar on RNA-Seq Data Analysis on 28 Feb 2018

Strand — Thu, 22 Feb 2018 06:38:48 -0600

Strand NGS is a biologist friendly NGS analysis tool that allows biologists to analyze their data using a very intuitive workflow for the analysis and visualization of RNA-Seq data. This webinar will give an overview of the workflow which includes Transcriptome/ Genome alignment, Differential expression analysis, Splicing events and gene fusion detection. Strand NGS also supports novel discovery like identification of novel genes, exons and novel splice junctions.
We will highlight the use of Strand NGS features such as PCA, sample correlation, clustering, Venn diagrams, CVA, UMI support and elastic genome browser used in RNA-Seq workflow that supports large scale RNA-Seq data analysis too. The tool also supports biological contextualization on the set of interesting genes from the data by allowing downstream analysis such as GO and pathway analysis. The product has an option to create pipelines for time consuming jobs which automates analysis and leaves more time for end data interpretation. This webinar will give an overview of the features in the RNA-Seq data analysis workflow in Strand NGS.

Details:
Session 1: 28 Feb 2018, 9 AM CET
Session 2: 28 Feb 2018, 8 AM PST
Register here: http://www.strand-ngs.com/webinar_registration

About Speaker:

Dr. Suman Kapoor, Manager- Application Science at Strand Life Sciences, has over 11 years experience in molecular biology, next-generation sequencing based testing, clinical genomics, and personalized medicine for disease management and prenatal testing. Dr. Suman holds a Ph.D in Molecular and Cell Biology from Indian Institute of Science, Bangalore. Prior to joining Strand NGS team, Suman has worked extensively on protein synthesis in eubacteria and has experience working in CAP and NABL accredited lab validating and interpreting NGS based diagnostic tests.

Strand Life Sciences announces the release of Strand NGS v3.1 at ASHG 2017

Yeshodari — Mon, 23 Oct 2017 02:36:05 -0500

Strand Life Sciences announces the release of Strand NGS v3.1 at ASHG 2017

ORLANDO, USA, Oct 17, 2017/ PRNewswire/

Strand NGS now supports large scale RNA- and small-RNA-Seq and Unique Molecular Identifiers (UMIs) for DNA-, RNA-, and small-RNA-Seq.

Strand Life Sciences announced the latest version release of its bioinformatics flagship product, Strand NGS, at the Annual Meeting of the American Society of Human Genetics today. Two major themes in Strand NGS v3.1 address recent challenges in next generation sequencing (NGS).

The first theme is large-scale RNA-Seq data analysis. Current cross-cohort RNA- and small-RNA-Seq studies span tens of replicates and batches across hundreds of samples, sometimes conducted across several different institutions. For such studies, Strand NGS v3.1 includes confounding variable analysis to eliminate technical effects, including batch effects; the t-SNE plot; profile and heat-map plots of gene-body coverage; and several other notable visual enhancements.

The second new feature is support for Unique Molecular Identifiers, or UMIs, for DNA-, RNA- and small-RNA-Seq. UMI support in Strand NGS is end-to-end, spanning alignment to variant calling in DNA-Seq, and alignment to quantification in RNA- and small-RNA-Seq. The Bioo Scientific, Qiagen, and Rubicon UMI protocols are natively supported, and an intuitive interface allows the specification of custom UMI protocols.

“For liquid biopsies and low-grade FFPE samples, UMI support in DNA-Seq enables the detection of somatic variants at low concentrations. In RNA-Seq, large-scale and UMI support can be used in single-cell-based studies that reveal tumor-cell heterogeneity, even at low concentrations”, says Dr. Vamsi Veeramachaneni, Chief Scientific Officer, Strand Life Sciences.

“At Strand, we are continuously working towards improving the accuracy and efficiency of NGS data analysis. Customers can look forward to Strand NGS becoming available on the cloud in the near future”, says Dr. Ramesh Hariharan, Chief Executive Officer, Strand Life Sciences.

Visit Strand Life Sciences at ASHG booth #1017 to know more about Strand NGS v3.1 and other products and service offerings from Strand Life Sciences. Click here to access detailed agenda and v3.1 release notes.

About Strand Life Sciences

Strand Life Sciences is a premier life science informatics innovation company. Founded in 2000, Strand is a leader in technology innovations for healthcare using genomics. By enhancing sequence-based diagnostics and clinical genomic data interpretation using a strong foundation of computational, scientific, and medical expertise, Strand is bringing individualized medicine to the world. To know more, visit www.strandls.com

Address of the bookmark: http://www.strand-ngs.com/strand-announce-strandngss-v31

Webinar on Diagnosis of Rare Diseases using NGS Based Multi-gene Testing- Case studies by Dr.Aparna Ganapathy on 18 Apr 2018

Strand — Mon, 19 Mar 2018 04:40:58 -0500

A disease is considered to be ‘rare’ when it affects one in about 2000 individuals in the population. This, individually are although rare, collectively, the incidence could be very high causing a significant socio-economic burden. Arriving at a confirmatory diagnosis is a major challenge in these inherited disorders, which can significantly impact treatment and disease management. Conventional genetic testing for rare diseases focuses mostly on sequencing of fewer genes, followed by a deletion/duplica-tion analysis by multiplex ligation-dependent probe amplifi¬cation (MLPA). This sequential testing strategy is time consuming and very expensive. Multi-gene panel based on NGS (next-generation sequencing) can allow us to detect all types of mutations, including large deletions/duplications, thus allowing us to perform a comprehensive genetic testing in a cost-effective manner. Thus, with the advent of NGS technology, the possibility of offering a ‘single platform solution’ for all types of genetic defects can become a reality.

The webinar will highlight some of the interesting case studies wherein multi-gene testing with NGS was helpful in arriving at a confirmatory as well as differential diagnosis, even for complex clinical conditions. With robust bioinformatic analysis, we were able to detect few complex variations in few cases which a conventional test had missed. Some of those cases will also be discussed.

Session 1: 9 am CET, 18 Apr 2018
Session 2: 8 am CET, 18 Apr 2018
To attend, register here: http://www.strand-ngs.com/webinar_registration

About Speaker: Dr. Aparna Ganapathy is Senior scientist- Clinical Diagnostics at Strand Life Sciences. She has over 8 years of experience in human genetics and molecular biology. She received her Ph.D. in Human Molecular Genetics from Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore. At Strand Life Sciences, she is involved in the interpretation and clinical reporting of the genetic disorders. The focus of these genetic tests is to provide accurate and rapid clinical diagnosis for various inherited disorders.

Strand Life Sciences announces the release of Strand NGS v3.1 at ASHG 2017

Yeshodari — Mon, 23 Oct 2017 02:39:24 -0500

Strand Life Sciences announces the release of Strand NGS v3.1 at ASHG 2017

ORLANDO, USA, Oct 17, 2017/ PRNewswire/

Strand NGS now supports large scale RNA- and small-RNA-Seq and Unique Molecular Identifiers (UMIs) for DNA-, RNA-, and small-RNA-Seq.

About Strand Life Sciences

Webinar on Fast and Accurate DNA Variant Calling on 26 Apr 2017

Yeshodari — Fri, 21 Apr 2017 06:14:37 -0500

Continuing our DNA-Seq webinar series, we'll present Strand NGS v3.0 best-practices: a workflow that identifies highly accurate variants from raw reads. Our best practices workflow is twice as fast as its GATK counterpart, and results in precision/recall rates of up to 99%/98% on whole exome and whole genome samples. We'll also speak briefly about some of the other features in v3.0 including one-shot pipelines, TSS plots, RNA-Seq performance improvements, and, for the first time, HGVS notations for SNP effect analysis.

Flow cytometry data analysis

Rahul Agarwal — Sat, 07 Sep 2013 18:09:48 -0500

Flow cytometry is a biophysical laser based instrument used in various purposes like cell counting, cell sorting, biomarker detection, etc.

Integrative RNA and ChIP-Seq analysis of regulatory T-cells

Strand — Tue, 04 Aug 2015 05:03:19 -0500

Integrative RNA and ChIP-Seq analysis of regulatory T-cells , a Strand NGS application note describes how integrated multi-omics functionality in Strand NGS was used to find the regulatory role of FoxP3 in T-regulatory and T-helper cells. Learn how the gene expression profiles from RNA-Seq and FoxP3 DNA-protein binding sites from ChIP-Seq are integrated. For mor information, please write to us

2013 Method of the Year

Rahul Agarwal — Wed, 01 Jan 2014 17:52:07 -0600

-Nature Publishing Group selected single-cell sequencing as Method of the Year for 2013.

->100 peer-reviewed single-cell publications based on Fluidigm technology

Source: http://online.wsj.com/article/PR-CO-20131231-904382.html

About Single-Cell Sequencing:

http://bernstein.harvard.edu/pages/news/nbt.2523.pdf